Open Label Extension of LipoLat-CS202

N/ACompletedNCT02599688

Peregrine Ophthalmic18 enrolled

Overview

This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Glaucoma

Interventions

Observation onlyOTHER

No intervention in this study.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

* Inclusion criteria 1. Successful completion of 3 months of participation in Study LipoLat-CS202. 2. Treatment with POLAT-001 in Study LipoLat-CS202. 3. Able and willing to give signed informed consent and follow study instructions. * Exclusion criteria Excluded from the study will be individuals with the following characteristics: 1\. The development, during study LipoLat-CS202, of any exclusion criteria from that study (e.g., concomitant medication or co-morbid disease).

Locations (1)

Professional Research Network

Goose Creek, South Carolina, United States

Outcomes

Primary Outcomes

Intraocular Pressure (IOP)

Mean change from baseline (Visit 1 in Study LipoLat-CS202, NCT02466399) IOP at Month 3 (6 months after treatment in LipoLat-CS202).

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.